Related references
Note: Only part of the references are listed.Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
A. Neuprez et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw
J. Narvaez et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges
D. H. Solomon et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw
Yumiko Ohbayashi et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2013)
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
Socrates Papapoulos et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis
Jean-Yves Reginster
DRUGS (2011)
Discontinuation of Odanacatib and Other Osteoporosis Treatments: Here Today and Gone Tomorrow?
Douglas C. Bauer
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Rene Rizzoli et al.
BONE (2008)
Share Paper
